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Purpose: Metabolomics is a global study of metabolites in biological samples. In this study
we explored whether serum metabolomic spectra could distinguish between early and
metastatic breast cancer patients and predict disease relapse.
Methods: Serum samples were analysed from women with metastatic (n ¼ 95) and predom-
inantly oestrogen receptor (ER) negative early stage (n ¼ 80) breast cancer using high reso-
lution nuclear magnetic resonance spectroscopy. Multivariate statistics and a Random
Forest classifier were used to create a prognostic model for disease relapse in early
patients.
Results: In the early breast cancer training set (n ¼ 40), metabolomics correctly distin-
guished between early and metastatic disease in 83.7% of cases. A prognostic risk model
predicted relapse with 90% sensitivity (95% CI 74.9e94.8%), 67% specificity (95% CI
63.0e73.4%) and 73% predictive accuracy (95% CI 70.6e74.8%). These results were repro-
duced in an independent early breast cancer set (n ¼ 40), with 82% sensitivity, 72% speci-
ficity and 75% predictive accuracy. Disease relapse was associated with significantly; CERM, Center of Magnetic Resonance; CPMG, CarrePurcelleMeiboomeGill; ER, oestrogen
, proton nuclear magnetic resonance; HER2, human epidermal growth factor receptor 2;
Sloan-Kettering Cancer Center; NOESY1D, nuclear overhauser effect spectroscopy pulse
operating curves.
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M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 2 8e1 3 9 129lower levels of histidine ( p ¼ 0.0003) and higher levels of glucose ( p ¼ 0.01), and lipids
( p ¼ 0.0003), compared with patients with no relapse.
Conclusions: The performance of a serummetabolomic prognostic model for disease relapse
in individuals with ER-negative early stage breast cancer is promising. A confirmation
study is ongoing to better define the potential of metabolomics as a host and tumour-
derived prognostic tool.
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reserved.1. Introduction et al., 2007). Breast cancer has been associated with markedBreast cancer is themost commonmalignancy andmost com-
mon cause of cancer death in women (Ferlay et al., 2010).
There is marked heterogeneity in breast cancer biology and
disease behaviour. Among individuals with seemingly similar
disease as assessed by clinico-pathological features, immuno-
histochemistry and molecular platforms, outcomes can be
substantially different.
The window of opportunity for curative intervention in
breast cancer is in early stage disease. Following surgical exci-
sion of the breast lesion and surgical sampling and/or dissec-
tion of axillary nodes, patients might be offered loco-regional
radiotherapy and/or post-operative (adjuvant) systemic ther-
apy. The rationale behind this approach is that residualmicro-
metastatic disease might be eradicated by chemotherapy,
targeted anti-human epidermal growth factor receptor 2
(HER2) therapy and/or targeted endocrine therapy. If not erad-
icated, micrometastases might progress to incurable dissemi-
nated breast cancer.
In current clinical practice adjuvant therapy is indicated on
the assumption of residualmicrometastases. The primary dis-
ease is assessed using traditional clinico-pathologic features
with or without gene profiling, and an estimation of the risk
of recurrence is thus made (Paik et al., 2004; Ravdin et al.,
2001). Micrometastatic disease is detectable, as circulating
tumour cells in the peripheral blood and disseminated tumour
cells in the bone marrow, although not all patients with
micrometastases will develop clinically evident macrometa-
static disease (Braun et al., 2005; Stathopoulou et al., 2002;
Xenidis et al., 2003). Factors beyond the presence of microme-
tastases, such as tumour cell dormancy, host immunity, and
the microenvironment, influence the clinical outcome.
Novel prognostic and predictive biomarkersmay refine risk
assessment and guide use of systemic therapy in individuals
with early breast cancer. In this setting there are promising
tools such as the various eomics, including metabolomics, a
science dedicated to the global study of small molecules and
metabolites (Nicholson, 2006). Metabolomics combines high
resolution data-rich analytical methodology with advanced
chemometric data interpretation. The ‘metabolome’, the
extensive analysis of hundreds of metabolites in a biological
specimen, can be considered the downstream end product
of the complex interaction of genome, transcriptome and pro-
teome. By its very nature of being downstream itmay be a very
sensitive tool for phenotype assessment.
The metabolome is affected by physiological, pathological
and iatrogenic factors (Griffin, 2003; Urbanczyk-Wochniakmetabolic shifts, which have been demonstrated inmany pre-
clinical and clinicalmetabolomic studies of breast cells, breast
tissue, serum and urine (Aboagye and Bhujwalla, 1999;
Budczies et al., 2012; Katz-Brull et al., 2002; Li et al., 2011;
Mackinnon et al., 1997; Mountford et al., 2001; Singer et al.,
1995). Metabolomics has been explored as a tool for diagnosis
of breast cancer, refined sub-classification of breast cancer,
and prediction of treatment sensitivity (Li et al., 2011;
Mountford et al., 2001; Asiago et al., 2010; Borgan et al., 2010;
Giskeodegard et al., 2012; Oakman et al., 2011; Slupsky et al.,
2010).
A potential strength of serum and urine metabolomic ana-
lyses is that this approach provides a composite metabolomic
snapshot of both the tumour and the host. By comparing sam-
ples from patients with early versus metastatic disease, host
features conducive to tumour progressionmight be identified,
with incorporation of both tumour and host factors from the
outset.
In view of the need for more refined prognostic estimation
in early breast cancer, we undertook this study to explore
whether metabolomics can add prognostic information in in-
dividuals with early breast cancer.We assessed serummetab-
olomic profiles in breast cancer patients using proton nuclear
magnetic resonance (1H NMR) spectroscopy, with two hypoth-
eses: (1) serum metabolomic profiles would be different be-
tween women following surgery for early breast cancer and
women with metastatic disease, due to tumour-specific
changes in the 1H NMR detectable metabolomic profile; and
(2) some patients with early breast cancer would be recog-
nized by metabolomic analysis as having metastatic disease
due to the presence of residual micrometastases.
We report serummetabolomic distinction betweenwomen
following surgery for early breast cancer and women with
metastatic disease, and further, we report metabolomic clas-
sification of a minority of early patients as metastatic, in
whom future disease relapse was more likely.2. Patients and methods
This was a collaborative project between the Breast Cancer
Medicine Service, Memorial Sloan-Kettering Cancer Center
(MSKCC), New York, United States; the Center of Magnetic
Resonance (CERM), University of Florence, Sesto Fiorentino,
Italy; and the ‘Sandro Pitigliani’ Medical Oncology Depart-
ment, Hospital of Prato, Prato, Italy.
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Ethics Committees at both MSKCC and the Hospital of Prato.
2.1. Patients
Serum samples were selected from the MSKCC breast can-
cer biobank. Patients attending the breast cancer medicine
service at MSKCC who provide written informed consent
and undergo standard serum biochemical analyses
routinely have left over serum stored at 80 C for future
research purposes. The Breast Cancer Medicine Service
maintains a database of all clinico-pathological data and
clinical outcomes.
This database was reviewed to identify cohorts of women
with early and metastatic breast cancer. Eligible early breast
cancer patients were required to have a post-operative serum
sample, collected before starting adjuvant therapy and within
90 days of surgery, with either documented disease relapse or
follow-up of at least five years with no relapse. Patients with
relapse were included regardless of oestrogen receptor (ER)
status. Conversely, the group without relapse was restricted
to patients with ER-negative disease, as five years of follow-
up was felt to be inadequate to exclude a relapse in ER-
positive disease in which relapse may occur out to 10 years.
As this was a retrospective study, all identified and suitable
early breast cancer patients, based on the above criteria,
were included. Eligible metastatic breast cancer patients
were required to have a post-diagnosis serum sample, and
were unrestricted with regards to ER status and duration of
metastatic disease.
Study serum samples (500 ml) were maintained at 80 C
from collection until transfer over dry ice from MSKCC to
CERM, where they were again stored at 80 C until analysis.
Serum samples and corresponding clinico-pathological data
were anonymized prior to transfer.
2.2. 1H NMR spectral acquisition
Frozen serum samples were thawed at room temperature and
shaken before use. A phosphate sodium buffer (300 ml, 70 mM,
pH 7.4) was added in a 1:1 ratio before analysis. The mixture
was homogenized by vortexing for 30 s. 450 ml were trans-
ferred into a 4.25 mm NMR tube (Bruker BioSpin srl).
1H NMR spectra for all samples were acquired using a
Bruker 600 MHz metabolic profiler (Bruker BioSpin) operating
at 600.13 MHz proton Larmor frequency and equipped with a
5 mm CPTCI 1He13C/31Pe2H cryoprobe including a z axis
gradient coil, an automatic tuning-matching (ATM) and an
automatic sample changer. A BTO 2000 thermocouple served
for temperature stabilization at the level of approximately
0.1 K at the sample. Before measurement, samples were
kept for at least three minutes inside the NMR probehead for
temperature equilibration (300 K).
For each sample, three 1H NMR spectra were acquired with
water peak suppression: (i) a standard nuclear Overhauser ef-
fect spectroscopy pulse sequence (NOESY1Dpresat; Bruker),
(ii) a CarrePurcelleMeiboomeGill (CPMG; Bruker) spin-echo
sequence to suppress signals arising from high molecular
weight molecules, (iii) a diffusion edited sequence
(ledbpgppr2s1d; Bruker) with a diffusion time of 120 ms.2.3. 1H NMR spectral processing
Free induction decays were multiplied by an exponential
function equivalent to a 1.0 Hz line-broadening factor before
applying Fourier transform. Transformed spectra were manu-
ally corrected for phase and baseline distortions and cali-
brated (TMSP peak at 0.00 ppm) using TopSpin (Version 2.1,
Bruker). Each 1D spectrum in the range between 0.02 and
10.00 ppm was segmented into 0.02 ppm chemical shift bins
and the corresponding spectral areas were integrated using
AMIX software (version 3.8.8, Bruker BioSpin). Regions be-
tween 4.5 and 6.0 ppm containing residual water signal were
removed. The total spectral area was calculated on the
remaining bins and data normalization was carried out prior
to pattern recognition. Binning is a means to reduce the num-
ber of total variables and to compensate for small shifts in the
signals, making the analysis more robust and reproducible
(Holmes et al., 1994; Spraul et al., 1994). Using 0.02 ppm
binning, the dimension of the systemwas reduced to 416 bins.
2.4. Statistical analysis
A statistical analysis planwas prepared before starting the an-
alyses, based on the results of a prior study from our group
(Oakman et al., 2011), where we first observed clusterization
of serum metabolomic spectra from early and advanced
breast cancer patients.
The size of the early breast cancer group was not pre-
defined and was based on the availability of suitable cases
with adequate clinical follow-up data and matched serum
samples. In contrast, it was determined that a sample size of
95 patients with metastatic breast cancer would be expected
to provide sufficient power (power ¼ 0.9, p < 0.05) to detect a
meaningful difference between this metastatic disease group
and the early breast cancer group (Cohen’s d ¼ 0.5).
The group of early breast cancer patients was randomly
split into two independent cohorts of equal patients number.
Initial analyses were restricted to patients in the first cohort
(hereafter referred to as the training set). The first step was
to establish if serum metabolomic profiles could distinguish
between patients with metastatic breast cancer and patients
post-recent surgery for operable primary breast cancer. This
analysis was unsupervised as to whether early breast cancer
patients developed relapse.
For discriminative models, a Random Forest (RF) classifier
(Breiman, 2001) was built to separate early breast cancer pa-
tients from patients with metastatic disease. RF is a classifica-
tion algorithm that uses an ensemble of unpruned decision
trees,eachofwhich isbuiltonabootstrapsampleof thetraining
data using a randomly selected subset of variables. RF can deal
with large numbers of predictor variables simultaneously, even
in the presence of complex non linear interactions (Strobl et al.,
2009) and it is almost immune fromtheoverfittingdue to the to-
tal number of variables in the data. This algorithm has many
strengths in metabolomics: i) it is applicable when there are
more variables than samples; ii) it is relatively insensitive to
noise; iii) it allows visualization of data in a reduced discrimi-
nant space using the proximity matrix calculated during the
process of forest growing; iv) the percentage of trees in the for-
est that assign one sample to a specific class can be interpreted
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timate of the classification error using the out-of-bag samples,
avoiding the need for time-consuming cross validation. The al-
gorithm begins with the selection of many bootstrap samples
from the original data. In a typical bootstrap sample, approxi-
mately 63% of the original observations occur at least once. Ob-
servations in the original data set that do not occur in a
bootstrap sample are defined as out-of-bag (OOB) observations.
A classification tree is fitted to each bootstrap sample but at
each node only a small number of randomly selected variables
(i.e. bins) are available for binarypartitioning. The treesare fully
grown, and each is used to predict the OOB observations. The
predicted class of an observation is calculated by the majority
voteof theOOBpredictions for that observation. This classifica-
tionrulewasusedtodiscriminatebetweenearlyandmetastatic
patients. The percentage of the total number of trees in the for-
est that classified a sample as early or metastatic can be inter-
preted as the probability of that sample belonging to that
group. The percentage of trees in themodel classifying an early
patient asmetastaticwas interpreted asameasureof themeta-
bolic risk of that patient. Hence, for early patients, a score that
expressed the probability of being metastatic was created and
designated as the ‘RF risk score’. For each patient, three ‘RF
risk scores’ were derived using the three types of spectra. We
assumedthathigher scorescorrelatedwithhigher riskofdevel-
oping a relapse. Importantly, the calculated RF score is not a
simple summation of the levels of several metabolites, but
rather, is a complex multivariate entity created using as input
the whole binned spectral data.
For all calculations, the R package ‘Random Forest’ (Liaw
and Wiener, 2002) was used to grow a forest of 1000 trees, us-
ing the default settings. Separate models were built for NOE-
SY1D, CPMG and Diffusion edited spectra. Statistical
analyses were performed using the R statistical environment
(Ihaka and Gentleman, 1996).
Thesecondstepwas to test thehypothesis thatmetabolomic
classification of some early patients as metastatic was due to
metabolomic detection of signals frommicrometastatic disease
with likelihood for progression to metastatic disease. Using
receiver operating characteristics (ROC) analysis, the perfor-
mances of the three RF risk scores were compared with actual
breast cancer outcome. Disease relapse was defined as loco-
regional and/or distant breast cancer recurrence documented
according to conventional clinico-radiological criteria, with pa-
thology confirmation required in the case of equivocal findings.
A prognostic model was created using the CPMG RF risk
score. The model was restricted to the CPMG score as this
had the highest predictive value in the training set. CPMG RF
risk scores were scaled to yield an integer score range of
0e100. Using actual follow-up data for patients who relapsed,
a CPMG RF score cut-off was calculated in the training set by a
judicious choice between sensitivity and specificity, then
maintained as a constant when used for the prediction of
relapse risk of all the samples in the ‘validation’ set. In addi-
tion, the CPMG RF risk score was evaluated in univariate and
multivariate analyses firstly with tumour size, nodal status
and age, and secondly with the Adjuvant!Online (http://
www.adjuvantonline.com) relapse risk score, to assess the
prognostic value of the metabolomic risk score in the context
of known clinico-pathological variables.2.5. Data reproduction in an independent set of patients
The process of choosing an appropriate threshold of the CPMG
RF score was a supervised analyses, in the sense that creation
and optimization of the model required information about
actual relapse. For this reason, the results required testing in
an independent set of early stage patients, designated for
simplicity as the validation set. However, in this context the
word ‘validation’ does not mean that results confirmed
through the validation set should be considered definitive.
2.6. Metabolite analysis
The NMR spectrum from each sample was aligned with refer-
ence to trimethylsilylpropionic-acid at 0 ppm. Spectral regions
within the range 0.5e9.0 ppm were analysed after excluding
the region between 4.5 and 6.0 ppm that contained the water
peak.
Differential metabolites levels between the metastatic and
early cohorts were analysed using the non parametric Wil-
coxon test. The intensities of the peaks were compared in
the raw spectra (without normalization) and after adjustment
for multiple testing using the Benjamini and Hochberg proce-
dure (Benjamini and Hochberg, 1995) to control the false dis-
covery rate. p values of <0.05 were considered significant.3. Results
3.1. Patients
From the MSKCC serum bank, 95 women with metastatic
breast cancer and 80womenwith early operable breast cancer
were identified. Stored serum samples had been collected be-
tween 2003 and 2010. Clinical and pathological characteristics,
which are listed in Table 1, were obtained from the biobank
database, with reference back to the patient’s electronic med-
ical record if clarification was required.
Most women with early breast cancer had received post-
operative systemic therapy: 54 (68%) women received chemo-
therapy. Of note, only 9 of 24 HER-2 positive patients received
trastuzumab-based adjuvant therapies. Three women (4%)
had ER-positive disease and all three received adjuvant endo-
crine therapywithout chemotherapy. Aminority of early stage
patients (n¼ 7 (9%)) had receivedneo-adjuvant chemotherapy.
Inclusion of these patients was considered reasonable as all
seven patients had a wash-out period of at least three weeks
between last dose of chemotherapy and post-surgery blood
sampling, andpatientsmay still have had residualmicrometa-
static disease not eradicated by neo-adjuvant treatment.
Early breast cancer patients were randomly split into a
trainingset (n¼40)andavalidationset (n¼40).Of the80patients
with early stage disease, 21 had documented disease relapse, 10
of whomwere in the training set and 11 in the validation set.
Patients with metastatic disease were similar in age to
those in the early breast cancer cohort. The majority of meta-
static patients (62%) had ER-positive disease. Twenty-four % of
patients had HER2 negative disease. The median time from
diagnosis of metastatic disease until blood sample was 59
days (range 2e1737). Samples from metastatic breast cancer











Age, mean (range) years 53 (28e80) 53 (31e88) 56 (31e88) 51 (32e78)
Tumour size
<2 cm NA 59 (74%) 29 (73%) 30 (75%)
2 cm 19 (24%) 10 (25%) 9 (23%)
Unknown 2 (2%) 1 (2%) 1 (2%)
Grade
I 1 (1%) 0 0 0
II 11 (11%) 2 (3%) 1 (2%) 1 (2%)
III 69 (73%) 69 (86%) 34 (85%) 35 (88%)
Unknown 14 (15%) 9 (11%) 5 (13%) 4 (10%)
Lymph node involvement
Node negative NA 41 (51%) 19 (48%) 22 (55%)
Node positive 39 (49%) 21 (52%) 18 (45%)
ER
Positive 59 (62%) 3 (4%) 2 (5%) 1 (2%)
Negative 33 (35%) 77 (96%) 38 (95%) 39 (98%)
Unknown 3 (3%) 0 0 0
HER2
Positive 23 (24%) 24 (30%) 14 (35%) 10 (25%)
Negative 71 (75%) 55 (69%) 25 (63%) 30 (75%)
Unknown 1 (1%) 1 (1%) 1 (2%) 0
Neo-adjuvant chemotherapy NA 7 (9%) 3 (8%) 4 (10%)
Adjuvant chemotherapy
None NA 16 (20%) 7 (17%) 9 (22%)
Chemotherapy 54 (68%) 27 (68%) 27 (68%)
Chemotherapy þ anti-HER2 therapy 9 (11%) 5 (13%) 4 (10%)
Unknown 1 (1%) 1 (2%) 0
Endocrine therapy 3 (4%) 2 (5%) 1 (2%)
ER: oestrogen receptor; HER2: human epidermal growth factor receptor 2; NA: not applicable.
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advanced disease. Of the 95 patients with advanced disease,
56 were deceased at the time of the present analysis. Median
overall survival for the deceased patients was 19 months
(range 1e58 months).
3.2. Spectra
NMR spectra of samples were obtained using NOESY1D, CPMG
and Diffusion editing, and showed clear signals for multiple
metabolites and small molecules.
3.3. Training set
Supervised analysis using RF showed spectra clusterization
from early and metastatic patients (Figure 1). Accuracy in pre-
dicting early or metastatic status was 83.7% (95% CI
83.6e83.9%) for CPMG, 86.7% (95% CI 86.4e86.8%) for NOE-
SY1D, and 84.4% (95% CI 83.6e85.1%) for Diffusion editing.
3.4. Comparison between RF risk scores and actual
relapse
Next, the hypothesis that metabolomic classification of some
early patients as metastatic was due to the presence of resid-
ual micrometastatic disease was tested by comparing metab-
olomic RF risk scores and actual relapse (Figure 2). Using ROCanalyses, the best prediction for RF score was seen with the
CPMG spectra, with area under the curve (AUC) of 0.863,
compared with AUC 0.817 and 0.607 for NOESY1D and Diffu-
sion editing spectra, respectively.3.5. Relapse prediction by CPMG RF risk score
The RF score is a continuous variable. In order to use this
approach to create a predictive model, a CPMG RF risk score
threshold for relapse was required. Accuracy of the RF risk
score was maximized using a threshold of 53, which yielded
sensitivity of 90% (95% CI 74.9e94.8%), specificity of 67% (95%
CI 63.0e73.4%), and overall accuracy for predicting likelihood
of relapse of 73% (95% CI 70.6e74.8%). For raw data, see
Additional Table 1.3.6. Data reproduction in an independent set of patients
The validation set was evaluated using an unsupervised anal-
ysis. Spectra of the validation samples were classified as
either ‘metastatic’ or ‘early’ using the CPMG RF risk score
model derived from the training set. Comparison between
metabolomic classification and actual outcome demonstrated
high correlation with AUC 0.824 (Figure 3). Using the CPMG RF
risk score threshold53, sensitivity, specificity, and predictive
accuracy were 82%, 72% and 75%, respectively.
Figure 1 e Clusterization of serum metabolomic profiles. Discrimination between metastatic (green, n [ 95) and early (red, n [ 40) breast cancer
patients using the random forest classifier. (a) CPMG; (b) NOESY1D; (c) Diffusion.
Figure 2 e Training set. Comparison between metabolomic classification and actual relapse. The receiver operator curves (ROC) and the area
under the curve (AUC) scores are presented for CPMG, NOESY1D and Diffusion.
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factors
The known prognostic factors age, tumour size and nodal sta-
tus were compared with CPMG RF risk score in univariate and
multivariate analyses. As all early stage patients had grade 3
tumours, histological grade was not included in the model.
In a univariate analysis tumour size, nodal status and RF
risk scorewere all significantly associatedwith relapse predic-
tion. Coefficients on univariate regression were 1.08, p ¼ 0.008
for tumour size; 0.69, p ¼ 0.011 for nodal status; and 7.24,
p ¼ 0.000138 for RF risk score, while the coefficient for age
was not statistically significant (0.008, p ¼ 0.68). In themulti-
variate regression model, which included tumour size, nodalFigure 3 e Validation set. Comparison between CPMG random
forest risk score metabolomic classification and actual relapse The
receiver operator curve (ROC) and the area under the curve (AUC)
score are presented for the CPMG analysis.status and RF score, tumour size and RF score showed a trend
toward significance (coefficients of 0.70, p ¼ 0.062, and 4.34,
p¼ 0.060 for tumour size and RF risk score, respectively), while
nodal status was no longer significantly associated with
relapse (coefficient 0.40, p ¼ 0.32), suggesting a moderate
dependence between these variables.
As an alternative means of evaluating the independent
prognostic value, the RF risk scorewas compared in univariate
and multivariate models with relapse risk as predicted by
Adjuvant!Online (AoL). AoL is an accepted and validated tool
that provides prognostic data based upon a patient’s clinico-
pathologic profile, incorporating data on age, comorbidities,
tumour size, grade, nodal status and ER status. It provides es-
timates of 10-year risk of disease relapse and death. For the
comparison with RF risk score, AoL risk score was calculated
as the 10-year risk of cancer relapse (in absence of adjuvant
therapy) using AoL (Standard Version 8.0). AoL risk score
was significantly associated with relapse in the univariate
model, with regression coefficient of 0.04, p¼ 0.0038. However,
in amultivariate analysis that incorporated AoL risk score and
RF risk score, only RF risk remained statistically significantly
associated with relapse (coefficient: 4.64, p ¼ 0.03), demon-
strating that RF risk score has independent prognostic value.3.8. Analysis of confounding factors
3.8.1. ER status
Due to the inclusion criteria for early stage patients, there was
a difference in ER status between the early and metastatic pa-
tient groups. In order to test for any confounding effects of the
ER status on theNMR profile, ER status predictionwas attemp-
ted using the Random Forest approach. This approach was
based on the principle that if no discrimination between ER-
positive and ER-negative patients on evaluation of the metab-
olomic spectra was seen, it implied that no observable effects
related to ER status are embedded in the serum NMR profile,
thus excluding ER status as a confounder in the present ana-
lyses of the spectra. For prediction, samples from 92
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negative). Samples from three patients with unknown ER sta-
tus were excluded. The overall accuracy for prediction of ER
status was 51.2% (95% CI 50.9e51.5%, p ¼ 0.68), with a sensi-
tivity of 46.2% (45.6e46.7%), and a specificity of 54.0% (95% CI
53.7e54.2%). These data suggest that ER status was not
encoded in the serum metabolome of patients and, therefore,
that ER status should not be considered a confounding factor
in the risk prediction analyses.
Furthermore, the analyses comparing spectra of early and
metastatic patients was repeated including only the ER-nega-
tive patients from both groups (n ¼ 77, and n ¼ 33 in the early
and metastatic groups, respectively), and showed comparable
results to the original analysis that incorporated all patients
irrespective of ER status. Overall accuracy was 82.4% (95%CI
82.3e82.6%), with a sensitivity of 82.4% (95% CI 82.2e82.6%),
and a specificity of 82.5% (95% CI 82.3e82.7%), demonstrating
again that a significant metabolic difference does exist be-
tween the metastatic and early cohorts.
3.8.2. Timing of serum sample
The time interval between surgery and the date of blood sam-
pling, which ranged from five to 80 days in the early breast
cancer cohort, was also explored as a potential confounder.
A model using the Random Forest classification was build to
evaluate if time interval between surgery and serum sample
collection could be predicted from the metabolomic data.
For this purpose a dichotomous variable was created, dividing
early samples into two categories: an interval of less than 30
days between surgery and collection and an interval of at least
30 days. No significant discrimination in metabolomic spectra
was seen based on this variable (accuracy ¼ 53.6%, 95% CI
53.5e53.8%), supporting lack of confounding by time interval
between surgery and serum sample collection.
3.9 Metabolites
An analysis of the NMR spectra was conducted to identify
which metabolites were contributing to the metastatic pro-
files. These metabolites were compared with metabolites
contributing to the profiles from early patients. All metastatic
patients and all early patients were included in these ana-
lyses. Relative serum concentrations of metabolites were esti-
mated through integration of the signals in the NMR spectra
and the comparison was performed using univariate Wil-
coxon test. Compared with profiles from early patients, serum
profiles from patients with metastatic disease had signifi-
cantly lower levels of histidine and significantly higher serum
levels of glucose, lactate, tyrosine and lipids. After correcting
for multiple testing, differences in tyrosine and lactate levels
were no longer statistically significant, while the other three
metabolites remained significantly different. Figure 4 depicts
the discriminant metabolites and the associated unadjusted
and adjusted p values.4. Discussion
In this study we employed serum 1H NMR spectral profiling
and advanced chemometric data analysis methods to identifya metabolomic signal associated with disease recurrence in
individuals with early breast cancer.
We observed distinction between serummetabolomic pro-
files of early andmetastatic breast cancer patients. This obser-
vation is consistent with results of our previous study, where
we found a discrimination between patients with early dis-
ease, whose blood sample was drawn pre-operatively, and pa-
tients with metastatic disease, with sensitivity of 75%,
specificity of 69%, and predictive accuracy of 72% (Oakman
et al., 2011), and with recently published data from Jobard
et al., who similarly demonstrated significant differentiation
between serum metabolomic profiles of early and metastatic
breast cancer patients (Jobard et al., 2014).
Furthermore in this current study we observed the prom-
ising performance by metabolomics for identification of early
patients with and without subsequent relapse. In particular,
we identified a CPMG RF signature in a training set of early
breast cancer patients, with the predictive utility of thismodel
reproduced in an independent set of patients. Clinical studies
clearly demonstrate that, while adjuvant chemotherapy im-
proves disease free survival, many patients treated with sur-
gery alone remain disease free in the long term. After 30
years of follow-up in node-positive disease and 20 years of
follow-up in node-negative ER-negative disease, approxi-
mately one quarter and one half of patients, respectively,
were disease free after surgery alone (Bonadonna et al., 2005).
There is still limited clinical capacity to identify these individ-
uals who do not require, and obtain no benefit from, adjuvant
intervention. With further validation, incorporation of this
approach into relapse risk assessment might allow identifica-
tion of patients with low metabolomic risk of relapse, who
have been cured by surgery alone, and thus who might be
spared adjuvant treatment and its associated toxicities.
Patients with subsequent disease relapse have the most to
potentially gain from adjuvant systemic therapy. A strength of
our study is that serum samples were collected prior to adju-
vant therapy and within a short period post-operatively (5e80
days), a clinically meaningful time for making adjuvant treat-
ment decisions. A recent study from Asiago et al. used a com-
bination of NMR and gas chromatographyemass spectroscopy
(GCeMS) to identify a serum metabolomic signal for early
detection of metastatic disease in individuals undergoing sur-
veillance following early breast cancer (Asiago et al., 2010).
These results are intriguing; howevermetastatic breast cancer
is incurable, whether diagnosed early or late and there
currently is no advantage to early detection of low volume,
asymptomatic metastatic disease. In contrast, detection of a
post-operative signal of micrometastatic disease and admin-
istration of curative-intent adjuvant systemic treatment
might alter clinical outcomes.
Many metabolites have been shown to correlate with
breast cancer development and progression (Aboagye and
Bhujwalla, 1999; Singer et al., 1995). Marked changes are re-
ported in cellular phospholipid metabolism, glycolysis and
amino acid metabolism (Aboagye and Bhujwalla, 1999; Katz-
Brull et al., 2002; Li et al., 2011; Griffin and Shockcor, 2004).
1H NMR metabolomic profiles contain qualitative and quanti-
tative information on hundreds of metabolites and small mol-
ecules (Aranibar et al., 2011; Serkova and Niemann, 2006). A
strength of non-targeted global spectrum analysis over
Figure 4 e Discriminant metabolites. Discriminant metabolites (p < 0.05) between profiles from early (green, n [ 80) and metastatic (red,
n [ 95) breast cancer patients. Box and whisker plots: horizontal line within the box [ mean; bottom and top lines of the box [ 25th and 75th
percentiles, respectively; bottom and top whiskers [ 5th and 95th percentiles, respectively. Median values (arbitrary units) are provided in the
associated table, along with raw p values and p values adjusted for multiple testing. pts: patients.
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 2 8e1 3 9136targeted analysis of specific metabolites is the lack of need to
make any assumptions on the identity of the metabolites that
are relevant for the selected pathology. Non-targeted profiles
capture a downstream readout of genetic signal, post-genomic signalling, cross-talk between signalling pathways,
and environmental influence. The complex metabolomic
signal that correlates with disease relapse is presumed to
contain metabolites relevant to residual micrometastatic
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response to the tumour.
In the current study the RF risk model used the entire NMR
spectra. Subsequently the spectra were interrogated to iden-
tify key discriminating metabolites. Patients with metastatic
disease were characterized by lower serum levels of histidine
and higher serum levels of glucose, lactate, tyrosine and
lipids, compared with post-operative early breast cancer sub-
jects who did not relapse. These results are consistent with
recent findings of Asiago et al., who also observed a reduction
in serum histidine and an increase in tyrosine and lactate in
womenwith a recurrent breast cancer, with respect to women
with a history of primary breast cancer without recurrence
(Asiago et al., 2010). Similarly, Jobard et al. demonstrated
higher levels of histidine in early compared with metastatic
breast cancer patients, while levels of several metabolites
including phenylalanine, pyruvate, glutamate and glycerol
were relatively higher in metastatic patients. Lipid levels
were also elevated, although this difference did not reach sta-
tistical significance (Jobard et al., 2014). High lipids have been
associated with high tumour cell proliferation, high cell mem-
brane turnover and lipid activity in intracellular signal trans-
duction (Aboagye and Bhujwalla, 1999; Katz-Brull et al., 2002;
Cuadrado et al., 1993). Increased serumNMR intensity for lipid
signals has also been attributed to inflammatory response in
cancer (Bertini et al., 2012). We found significantly higher in-
tensity of lipid signal resonances in patients with metastatic
disease which may, at least in part, reflect a non-specific in-
flammatory response. Further cross-study comparison of spe-
cific metabolites is limited due to diversity in biospecimen
(tissue, urine and serum), metabolomic platform (NMR and/
or MS) and chemometric approach in published metabolomic
literature in breast cancer to date.
One of the great challenges of metabolomic analyses is
variation: innate physiological variability for individuals and
biological variability for tumours. For any one person the pro-
file may change with diet, diurnal rhythm, body flora, drugs,
pathology and exercise. Between individuals, there is meta-
bolic variation based on age, gender, race and hormonal status
(Bollard et al., 2005). In this study, serum samples were
sourced from one hospital and a single sample was analysed
for each patient. In future studies it will be important to collect
more than one sample per patient and to standardize the
collection procedures (for instance, by defining a specific
time of the day for blood samples drawing, preferably before
any food and/or medication intake). In addition, in future
studies it will be important to have samples collected in a
limited time frame, while in the presented study samples
were collected between years 2003 and 2010.
There are limitations of our study. Firstly, patient numbers
are limited. We included all suitable early breast cancer pa-
tients identified in the MSKCC serum biobank and clinical
database, andmoreover we were able to reproduce results ob-
tained in the training set in a small but independent ‘valida-
tion’ cohort. Nonetheless, further evaluation of the RF risk
model in a larger patient cohort is required before any incor-
poration of a metabolomic risk model into clinical practice.
Furthermore, the majority of early breast cancer patients in
this study (79%) received adjuvant systemic therapy. This is
a potential confounding factor, as chemotherapy may havechanged the outcome predicted from the post-operative,
pre-chemotherapy sample. Early stage patients who were
classified as metastatic by the metabolomic prognostic model
may have been cured by adjuvant chemotherapeutic eradica-
tion of micrometastatic disease, in which case the utility of
the model would be underestimated. Conversely, patients
classified as early stage by the model may have had residual
disease that was subsequently eradicated, a scenario where
the prognostic value of the model would be overestimated.
This can be particularly relevant in the subset of HER-2 posi-
tive patients who received trastuzumab-based adjuvant
therapies.
In the current study, the analyses focused on early patients
with ER-negative disease, with ER-negative disease
comprising 96% of the early stage cohort. Patients with ER-
positive disease were excluded unless they had relapsed
within five years, due to concern that follow-up of five years
was not of adequate duration to evaluate relapses in ER-
positive disease, where recurrences may occur out to ten
years. Importantly, we evaluated the performance of the RF
risk model in the early stage patients excluding the three pa-
tients with ER-positive disease and found no significant differ-
ence in results (data not shown). Furthermore, metabolomic
spectra showed no significant clusterization based on ER sta-
tus, suggesting that ER status, while being clinically relevant,
did not unduly influence the utility of the metabolomic risk
model, and that differences in ER status between the early
and metastatic disease groups did not confound the results
obtained. Nonetheless, it will be important to explore whether
the results from this prognostic model are reproducible in pa-
tients with ER-positive early breast cancer. A follow-up study
has now been commenced, which aims to evaluate themetab-
olomic risk model in a much larger cohort of women with
early stage, and ER-positive, breast cancer, thus addressing
two limitations of the current study.
It is also of interest to explore how metabolomic ap-
proaches might be integrated with other prognostic informa-
tion derived from the host, tumour and micrometastatic
disease. Based on this concept, in a separate ongoing study,
we are exploring whether there is prognostic synergy between
metabolomic serum analyses and genomic assessment of the
tumour.5. Conclusions
The complexity of breast cancer biology and behaviour sug-
gests that a multi-platform approach to risk assessment in
early breast cancer is preferable to optimize risk prediction ac-
curacy. In this study we have identified a serum metabolomic
prognostic model for prediction of disease relapse in individ-
uals with early stage breast cancer, that appears to have inde-
pendent prognostic value over known prognostic clinico-
pathological variables. Importantly, results of this study
should be seen as exploratory, due to the aforementioned lim-
itations such as retrospective design, limited sample size, and
lack of data relating to ER-positive early stage patients. None-
theless, our results are promising as they suggest, for the first
time, that detection of host and/or tumour-derived metabolo-
mic signals assessed on serum samples taken before adjuvant
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 2 8e1 3 9138therapy may be informative with regard to individual patient
outcomes. A validation study is ongoing, which aims to better
define the potential of metabolomics as a host and tumour-
derived prognostic tool.Conflict of interest
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